Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** LICENSE AGREEMENTLicense Agreement • December 6th, 2016 • Therapix Biosciences Ltd. • Pharmaceutical preparations
Contract Type FiledDecember 6th, 2016 Company IndustryThis License Agreement (the "Agreement"), dated as of May 20, 2015 by and between Dekel Pharmaceuticals Ltd., corporate number 51-419250-9, a private company incorporated under the laws of Israel (the “Licensor”), and Therapix Biosciences Ltd., company number 51-358165-2, a public company whose shares are listed for trading on the Tel Aviv Stock Exchange ("TASE" and collectively, the “Licensee”). Licensee, on the one hand, and Licensor, on the other, may each individually be referred to in this Agreement as a “Party” and collectively referred to in this Agreement as the “Parties”.
Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** LICENSE AGREEMENTLicense Agreement • November 4th, 2016 • Therapix Biosciences Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 4th, 2016 Company IndustryThis License Agreement (the "Agreement"), dated as of May 20, 2015 by and between Dekel Pharmaceuticals Ltd., corporate number 51-419250-9, a private company incorporated under the laws of Israel (the “Licensor”), and Therapix Biosciences Ltd., company number 51-358165-2, a public company whose shares are listed for trading on the Tel Aviv Stock Exchange ("TASE" and collectively, the “Licensee”). Licensee, on the one hand, and Licensor, on the other, may each individually be referred to in this Agreement as a “Party” and collectively referred to in this Agreement as the “Parties”.
Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** LICENSE AGREEMENTLicense Agreement • October 7th, 2016 • Therapix Biosciences Ltd. • Pharmaceutical preparations
Contract Type FiledOctober 7th, 2016 Company IndustryThis License Agreement (the "Agreement"), dated as of May 20, 2015 by and between Dekel Pharmaceuticals Ltd., corporate number 51-419250-9, a private company incorporated under the laws of Israel (the “Licensor”), and Therapix Biosciences Ltd., company number 51-358165-2, a public company whose shares are listed for trading on the Tel Aviv Stock Exchange ("TASE" and collectively, the “Licensee”). Licensee, on the one hand, and Licensor, on the other, may each individually be referred to in this Agreement as a “Party” and collectively referred to in this Agreement as the “Parties”.